Acquired Resistant Mechanism of the First-generation EGFR TKIs

Zhejiang Cancer Hospital60 enrolled

Overview

Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable genetic mutations can be helpful for guiding the subsequent treatment. This study aimed to analyze the genetic profile of NSCLC harboring acquired resistance to the first-generation EGFR TKIs using next generation sequencing (NGS).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non-small Cell Lung Cancer Aquired Resistance EGFR TKIs

Interventions

Genetic: mutation profileOTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically proven stage IIIB or IV non-small cell lung cancer * patients harboring sensitive EGFR mutations and received first-generation EGFR-TKIs who developed acquired drug resistance * patients who can provide pre-treatment (EGFR TKIs) tumor tissues * patients with tumor lesions to be re-biopsy after drug resistance * patients must sign an informed consent indicating that they are aware of the .investigational nature of the study in keeping with the policy of the hospital. Exclusion Criteria: * History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * patients with other systemic diseases

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

mutation profile

Time frame: 10 days

Central Contacts

Ying Jin, MD

CONTACT

86-571-88122082 jinying_1987@sina.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.